Free Trial
NASDAQ:HOOK

Hookipa Pharma Q1 2025 Earnings Report

Hookipa Pharma logo
$1.34 +0.02 (+1.52%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.36 +0.02 (+1.87%)
As of 05/2/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hookipa Pharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.61
Beat/Miss
N/A
One Year Ago EPS
N/A

Hookipa Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.38 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hookipa Pharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Hookipa Pharma Earnings Headlines

Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Hookipa Pharma Drops Poolbeg Takeover Bid
See More Hookipa Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hookipa Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hookipa Pharma and other key companies, straight to your email.

About Hookipa Pharma

Hookipa Pharma (NASDAQ:HOOK)., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

View Hookipa Pharma Profile

More Earnings Resources from MarketBeat